RU2768868C2 - Соединения, предназначенные для лечения ожирения, и способы их применения - Google Patents

Соединения, предназначенные для лечения ожирения, и способы их применения Download PDF

Info

Publication number
RU2768868C2
RU2768868C2 RU2018112067A RU2018112067A RU2768868C2 RU 2768868 C2 RU2768868 C2 RU 2768868C2 RU 2018112067 A RU2018112067 A RU 2018112067A RU 2018112067 A RU2018112067 A RU 2018112067A RU 2768868 C2 RU2768868 C2 RU 2768868C2
Authority
RU
Russia
Prior art keywords
celastrol
dosage form
obesity
mice
administered
Prior art date
Application number
RU2018112067A
Other languages
English (en)
Russian (ru)
Other versions
RU2018112067A3 (cg-RX-API-DMAC7.html
RU2018112067A (ru
Inventor
Умут ОЗКАН
Джозеф МАДЖЗУБ
Ральф Мацичек
Исин ЧАКИР
Серкан ЧАБИ
Original Assignee
Дзе Чилдрен'З Медикал Сентер Корпорейшн
Дзе Дженерал Хоспитал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2768868(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Чилдрен'З Медикал Сентер Корпорейшн, Дзе Дженерал Хоспитал Корпорейшн filed Critical Дзе Чилдрен'З Медикал Сентер Корпорейшн
Publication of RU2018112067A publication Critical patent/RU2018112067A/ru
Publication of RU2018112067A3 publication Critical patent/RU2018112067A3/ru
Application granted granted Critical
Publication of RU2768868C2 publication Critical patent/RU2768868C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2018112067A 2012-09-27 2013-09-26 Соединения, предназначенные для лечения ожирения, и способы их применения RU2768868C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
US61/706,153 2012-09-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015115696A Division RU2650646C2 (ru) 2012-09-27 2013-09-26 Соединения, предназначенные для лечения ожирения, и способы их применения

Publications (3)

Publication Number Publication Date
RU2018112067A RU2018112067A (ru) 2019-03-07
RU2018112067A3 RU2018112067A3 (cg-RX-API-DMAC7.html) 2021-06-24
RU2768868C2 true RU2768868C2 (ru) 2022-03-25

Family

ID=49304418

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018112067A RU2768868C2 (ru) 2012-09-27 2013-09-26 Соединения, предназначенные для лечения ожирения, и способы их применения
RU2015115696A RU2650646C2 (ru) 2012-09-27 2013-09-26 Соединения, предназначенные для лечения ожирения, и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015115696A RU2650646C2 (ru) 2012-09-27 2013-09-26 Соединения, предназначенные для лечения ожирения, и способы их применения

Country Status (21)

Country Link
US (6) US9968575B2 (cg-RX-API-DMAC7.html)
EP (3) EP4082541A1 (cg-RX-API-DMAC7.html)
JP (2) JP6480864B2 (cg-RX-API-DMAC7.html)
CN (3) CN111529535A (cg-RX-API-DMAC7.html)
AU (3) AU2013323528B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015006848A2 (cg-RX-API-DMAC7.html)
CA (2) CA3030272C (cg-RX-API-DMAC7.html)
CY (1) CY1121166T1 (cg-RX-API-DMAC7.html)
DK (1) DK2900230T3 (cg-RX-API-DMAC7.html)
ES (1) ES2696626T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181879T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040496T2 (cg-RX-API-DMAC7.html)
LT (1) LT2900230T (cg-RX-API-DMAC7.html)
PL (1) PL2900230T3 (cg-RX-API-DMAC7.html)
PT (1) PT2900230T (cg-RX-API-DMAC7.html)
RS (1) RS58010B1 (cg-RX-API-DMAC7.html)
RU (2) RU2768868C2 (cg-RX-API-DMAC7.html)
SI (1) SI2900230T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800604T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815668T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014052583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
ES2813424T3 (es) * 2014-03-26 2021-03-23 Childrens Medical Ct Corp Derivados de celastrol para el tratamiento de la obesidad
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
CN108601751A (zh) * 2015-10-23 2018-09-28 Erx制药股份有限公司 雷公藤红素的类似物
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
WO2023038575A2 (en) * 2021-09-09 2023-03-16 Junion Labs Pte. Ltd. Superabsorbent hydrogels with lipase inhibitor
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US20070160692A1 (en) * 2002-10-21 2007-07-12 Tripp Matthew L Compositions that treat or inhibit pathological conditions associated with inflammatory response
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
CZ416797A3 (cs) 1995-06-30 1998-06-17 Eli Lilly And Company Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
NZ512083A (en) 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法
HUP9904023A3 (en) 1996-09-20 2002-01-28 Hoechst Ag Use of leptin antagonists for treating insulin resistance in type ii diabetes
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
RS49927B (sr) 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
KR20010013414A (ko) 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
WO2005069415A1 (ja) 2004-01-16 2005-07-28 Mitsubishi Materials Corporation 燃料電池用セパレータ、セパレータの製造方法および固体酸化物形燃料電池
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
US8236769B2 (en) 2005-09-30 2012-08-07 Morinaga Milk Industry Co., Ltd. Agent for improving insulin resistance
EP2604269B1 (en) 2005-11-01 2014-09-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (en) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CN101939022A (zh) * 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
AU2009332930A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
JP5780549B2 (ja) 2009-04-17 2015-09-16 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
TWI558724B (zh) 2010-04-12 2016-11-21 瑞塔醫藥有限責任公司 利用抗氧化發炎調節劑治療肥胖之方法
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
AU2011292959B2 (en) 2010-08-23 2016-06-09 Suzhou Neupharma Co., Ltd. Certain chemical entities, compositions, and methods
EP2617726A4 (en) * 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
US9533002B2 (en) 2012-05-25 2017-01-03 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US20070160692A1 (en) * 2002-10-21 2007-07-12 Tripp Matthew L Compositions that treat or inhibit pathological conditions associated with inflammatory response
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes

Also Published As

Publication number Publication date
EP2900230B1 (en) 2018-08-15
AU2013323528A1 (en) 2015-04-09
RS58010B1 (sr) 2019-02-28
CN111529534A (zh) 2020-08-14
BR112015006848A2 (pt) 2018-05-22
RU2015115696A (ru) 2016-11-20
LT2900230T (lt) 2019-01-10
US20170304245A1 (en) 2017-10-26
CA3030272C (en) 2021-09-28
CA3030272A1 (en) 2014-04-03
US20210008019A1 (en) 2021-01-14
US20250161252A1 (en) 2025-05-22
AU2013323528B2 (en) 2016-11-10
US12064408B2 (en) 2024-08-20
JP6743211B2 (ja) 2020-08-19
TR201815668T4 (tr) 2018-11-21
CA2886393C (en) 2019-02-26
SMT201800604T1 (it) 2019-01-11
AU2018256619B2 (en) 2020-07-23
SI2900230T1 (sl) 2019-01-31
ES2696626T3 (es) 2019-01-17
AU2018256619A1 (en) 2018-11-22
EP2900230A1 (en) 2015-08-05
JP6480864B2 (ja) 2019-03-13
EP4082541A1 (en) 2022-11-02
HRP20181879T1 (hr) 2019-02-08
US9968575B2 (en) 2018-05-15
CN104822374A (zh) 2015-08-05
PL2900230T3 (pl) 2019-02-28
HUE040496T2 (hu) 2019-03-28
EP3434268A1 (en) 2019-01-30
US20210275482A1 (en) 2021-09-09
RU2650646C2 (ru) 2018-04-16
CY1121166T1 (el) 2020-05-29
AU2016247206B2 (en) 2018-08-02
JP2015531376A (ja) 2015-11-02
US20150250753A1 (en) 2015-09-10
HK1213190A1 (en) 2016-06-30
EP3434268B1 (en) 2022-04-20
CA2886393A1 (en) 2014-04-03
RU2018112067A3 (cg-RX-API-DMAC7.html) 2021-06-24
RU2018112067A (ru) 2019-03-07
US11045439B2 (en) 2021-06-29
AU2016247206A1 (en) 2016-11-10
US10653654B2 (en) 2020-05-19
WO2014052583A1 (en) 2014-04-03
DK2900230T3 (en) 2018-11-12
US20180185314A1 (en) 2018-07-05
CN111529535A (zh) 2020-08-14
US9925161B2 (en) 2018-03-27
JP2019070052A (ja) 2019-05-09
PT2900230T (pt) 2018-11-26

Similar Documents

Publication Publication Date Title
RU2768868C2 (ru) Соединения, предназначенные для лечения ожирения, и способы их применения
RU2706239C2 (ru) Целастрол и его производные для лечения ожирения
AU2018200517B2 (en) Compounds for the treatment of obesity and methods of use thereof
HK40083451A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034039A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034040A (en) Compounds for the treatment of obesity and methods of use thereof